Itgo 50DT Tablet contains Itraconazole 50 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itgo 50DT is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and dermatophytosis. The tablet is designed for oral administration and offers convenient dosing with improved bioavailability. It is particularly effective against infections caused by Candida species, dermatophytes, and other pathogenic fungi. Dosage and duration of therapy should be individualized based on the type and severity of infection, patient response, and clinical judgment. Caution is advised in patients with hepatic impairment, congestive heart failure, or those receiving concomitant medications metabolized by the cytochrome P450 system due to potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash, while serious adverse reactions are rare but may include hepatotoxicity and cardiac events. Regular monitoring of liver function and clinical status is recommended during prolonged therapy. Itgo 50DT Tablet should be used under medical supervision to ensure safety and efficacy.